Pertaining Elto Pharma, June 7 release stated "1)
Post# of 30027
(Total Views: 408)
Posted On: 07/20/2018 2:34:07 PM
Pertaining Elto Pharma, June 7 release stated "1) standalone private funding followed by a US or Hong Kong-based IPO, or 2) a business combination with an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline in which Amarantus could become a significant shareholder. Amarantus expects to make a final determination on the capital formation plan for Elto Pharma in the summer of 2018."
Today's release stated " In parallel with this, the Company is finalizing the plans for Elto Pharma and Cutanogen that it believes will drive near-term value as those subsidiaries prepare to re-enter clinical development."
It is clear AMBS is having difficulty getting stand alone private funding. Since the plan is to start clinical trials for both in the first half of 2019, it seems to me the only thing that would drive near-term value is joint ventures with biopharma companies.
GOOD: They are still executing the plan as outlined earlier. At current price rate, the stock is a great speculative buy.
BAD: They are also hedging if all form of clean financing fails to materialize, they would raise money by issuing securities or long term debt. That could potentially mean issuing more shares. Mr. Chan is a wild card, how long is he willing to remain patient before he starts unloading his shares?
Today's release stated " In parallel with this, the Company is finalizing the plans for Elto Pharma and Cutanogen that it believes will drive near-term value as those subsidiaries prepare to re-enter clinical development."
It is clear AMBS is having difficulty getting stand alone private funding. Since the plan is to start clinical trials for both in the first half of 2019, it seems to me the only thing that would drive near-term value is joint ventures with biopharma companies.
GOOD: They are still executing the plan as outlined earlier. At current price rate, the stock is a great speculative buy.
BAD: They are also hedging if all form of clean financing fails to materialize, they would raise money by issuing securities or long term debt. That could potentially mean issuing more shares. Mr. Chan is a wild card, how long is he willing to remain patient before he starts unloading his shares?
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼